Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.78, $0.04 better than the analyst estimate of $0.74. Revenue for the quarter came in at $1.74 billion versus the consensus estimate of $1.7 billion.

GUIDANCE:

Edwards Lifesciences sees FY2026 EPS of $2.95-$3.05, versus the consensus of $3.01.

Increasing total company constant currency2 sales growth guidance: 10% to 11% from 9% to 11%
Increasing TAVR constant currency2 sales growth guidance: 8% to 9% from 7% to 9%
Increasing TMTT sales guidance: $760 to $780 million from $740 to $780 million

Expected clinical presentations at TCT: PROGRESS and CLASP IITR
Expected Q4 approvals of PASCAL tricuspid indication in U.S. and next-generation PASCAL with Capture Clarity in U.S. and Europe

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.